{"SPADE_UN_17847": {"Clinical Information": [], "Patent Information": [{"Patent No": "CN112010959A", "Patent Link": "http://www.lens.org/lens/patent/CN112010959A", "Patent Type": "Granted Patent", "Publication Date": "2020-12-1", "Family Info": "Notavailable", "Patent Title": "Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof", "Abstract": "The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like."}, {"Patent No": "CN112010959A", "Patent Link": "http://www.lens.org/lens/patent/CN112010959A", "Patent Type": "Granted Patent", "Publication Date": "2020-12-1", "Family Info": "Notavailable", "Patent Title": "Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof", "Abstract": "The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like."}, {"Patent No": "CN112010959A", "Patent Link": "http://www.lens.org/lens/patent/CN112010959A", "Patent Type": "Granted Patent", "Publication Date": "2020-12-1", "Family Info": "Notavailable", "Patent Title": "Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof", "Abstract": "The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like."}, {"Patent No": "CN112010959A", "Patent Link": "http://www.lens.org/lens/patent/CN112010959A", "Patent Type": "Granted Patent", "Publication Date": "2020-12-1", "Family Info": "Notavailable", "Patent Title": "Novel alpha O-conotoxin peptide GeXIVA new mutant as well as pharmaceutical composition and application thereof", "Abstract": "The invention belongs to the fields of biochemistry, molecular biology and neuroscience, and relates to a novel alpha O-conotoxin GeXIVA mutant, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide, the amino acid sequence of which is that one or more amino acids in a mother sequence are removed, or one or more amino acids in the mother sequence are replaced by L-type amino acids or D-type amino acids with the same number, wherein the mother sequence is SEQ ID NO. 1, SEQ ID NO. 62 or SEQ ID NO. 63; and the polypeptide has activity of blocking alpha 9 alpha 10 nAChR. The polypeptide can specifically block alpha 9 alpha 10nAChR, and has good application prospect in the aspects of preparing analgesic drugs, drugs for treating mental diseases and cancers, neuroscience tool drugs and the like."}], "Sequence Information": {"SPADE ID": "SPADE_UN_17847", "Sequence": "TCRSSGRYCRSPYDRRARYCRRITDACV", "Sequence Length": 28, "Peptide Name": "[R17A]GexIVA[1,2]", "Source": "Synthetic", "Biological Activity": ["Antimicrobial", "Anticancer"], "Frequent Amino Acids": "RCS", "Absent Amino Acids": "EFHKLMNOQUW", "Basic Residues": 8, "Acidic Residues": 2, "Hydrophobic Residues": 8, "Polar Residues": 23, "Positive Residues": 8, "Negative Residues": 2, "Mass": 3371.82, "PI": 9.92, "Net Charge": 6, "Hydrophobicity": -1.09, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_17878", "Similarity": 1.0, "Sequence": "RSPYDRRARY"}, {"SPADE_ID": "SPADE_N_07419", "Similarity": 0.9642857142857143, "Sequence": "TCRSSGRYCRSPYDRRRRYCRRITDACV"}, {"SPADE_ID": "SPADE_UN_17863", "Similarity": 0.9642857142857143, "Sequence": "TCRSSGRYCRSPYDARARYCRRITDACV"}]}}}